Skip to content
Evigrade

Hydroxycarbamide

AEMPS

Cytostatic agents (other antineoplastic agents, ribonucleotide reductase inhibitor)

ATC code: L01XX05

Brand names: Hydrea, Droxia, Siklos

Updated · Methodology

Indications

A

Essential thrombocythemia

First line

Hydroxycarbamide is a cytostatic drug that suppresses dividing bone marrow cells and lowers the platelet count. In essential thrombocythemia it is used under the Hydrea ficha técnica (AEMPS), which lists the disease among the myeloproliferative syndromes. The ficha gives a loading dose of 25 to 50 mg/kg a day and a maintenance dose of 10 to 20 mg/kg; the dose is then adjusted to blood counts and continued while platelets and white cells stay controlled. The European LeukemiaNet recommendations (ELN 2018) group patients by age and thrombosis: high risk means age 60 or older or a prior thrombosis. Hydroxycarbamide was tested in RCTs in exactly these patients. In the Cortelazzo trial (NEJM 1995, 114 patients), thrombosis occurred over a median of 27 months in 3.6 percent on hydroxycarbamide and in 24 percent without cytoreduction. In PT-1 (NEJM 2005, 809 patients, all on low-dose aspirin), the composite endpoint of arterial and venous thrombosis, serious bleeding or death from them was reached more often on anagrelide than on hydroxycarbamide (OR 1.57). Anagrelide brought more arterial thrombosis, serious bleeding and transformation to myelofibrosis, but less venous thromboembolism. ELN 2018 recommends hydroxycarbamide or interferon alfa as first-line therapy when cytoreduction is needed, and anagrelide or interferon as second line after hydroxycarbamide fails or is not tolerated. With long-term use the ficha describes leg ulcers in about 9 percent of patients and skin cancer, so the skin is checked regularly.

ICD-10: D47.3

A

Sickle cell disease

First line

Hydroxycarbamide is a cytostatic drug. In sickle cell anemia it raises the share of fetal hemoglobin (HbF) and lowers the neutrophil count, so red cells deform and block small vessels less often. In Spain the product for this indication is Siklos (100 and 1000 mg tablets, authorization). Per the ficha técnica it is used to prevent recurrent painful vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years with symptomatic sickle cell anemia. The oral solution Xromi is also EMA-authorized but does not appear in CIMA. In the double-blind MSH trial (NEJM 1995, 299 adults with 3 or more crises a year), the median crisis rate was 2.5 per year on hydroxycarbamide versus 4.5 on placebo; acute chest syndrome occurred in 25 versus 51 patients, and 48 versus 73 needed transfusions. In BABY HUG (Lancet 2011), children aged 9 to 18 months had 177 versus 375 pain events and 24 versus 123 episodes of dactylitis. The 2017 Cochrane review confirms less pain, acute chest syndrome and transfusion in HbSS and HbSβ0 genotypes, but data on long-term benefit and harm, fertility included, are limited. The NHLBI expert panel (JAMA 2014) strongly recommends hydroxycarbamide for adults with 3 or more severe crises in a year, with pain or anemia that interferes with daily life, or with severe or recurrent acute chest syndrome, and suggests offering it to children regardless of symptoms. Per the Siklos ficha the starting dose is 15 mg/kg a day, the usual dose 15 to 30 mg/kg, and in exceptional cases up to 35 mg/kg under close blood monitoring. If there is still no response after 3 to 6 months at 35 mg/kg, the ficha suggests considering stopping. With creatinine clearance of 60 mL/min or less the starting dose is halved, and below 30 mL/min the drug is contraindicated. Treatment is started by a doctor experienced in sickle cell anemia.

ICD-10: D57 · ICD-11: 3A51.2

B

Polycythemia vera

First line

Hydroxycarbamide is a cytostatic drug that suppresses excess blood cell production in the bone marrow. In polycythemia vera the Hydrea ficha técnica (AEMPS) allows it when phlebotomy alone does not control the disease. Per the European LeukemiaNet recommendations (ELN 2018), treatment is based on phlebotomy and low-dose aspirin. The phlebotomy target is a hematocrit below 45 percent. Cytoreduction is added at high thrombotic risk, meaning age over 60 or a prior thrombosis, and also with poor tolerance of phlebotomy, progressive splenomegaly, platelets above 1500 × 10⁹/L or white cells above 15 × 10⁹/L. In high-risk patients first-line options are hydroxycarbamide or interferon alfa at any age, but ELN 2018 advises caution with hydroxycarbamide in young patients and prefers interferon for long-term treatment. ELN 2021 (Lancet Haematology 2022) recommends recombinant interferon alfa, either ropeginterferon alfa-2b or peginterferon alfa-2a, for patients under 60 without prior thrombosis who need cytoreduction. The ficha gives a loading dose of 15 to 20 mg/kg a day and a maintenance dose of 10 mg/kg, which for most patients means 500 to 1000 mg a day, with a full blood count every 6 to 8 weeks. In a Spanish cohort (Alvarez-Larrán et al, Blood 2012, 261 patients), 11 percent were resistant to hydroxycarbamide and 13 percent intolerant, and resistance was linked to a higher risk of death (HR 5.6). With resistance or intolerance, ELN 2018 recommends switching to interferon alfa or ruxolitinib.

ICD-10: D45

C

Chronic myeloid leukemia

Adjunct

Hydroxycarbamide is a cytostatic drug that lowers the white cell count quickly. In chronic myeloid leukemia (CML) the Hydrea ficha técnica (AEMPS) allows it in two situations: before definitive treatment, when leukocytosis needs to come down fast, and as palliation when the disease resists other options or the patient cannot tolerate them. The ficha gives a loading dose of 30 to 60 mg/kg a day and a maintenance dose of 15 to 30 mg/kg. Definitive treatment of CML today is a tyrosine kinase inhibitor. The 2020 European LeukemiaNet recommendations list imatinib (brand or generic), dasatinib, nilotinib or bosutinib as first line. With these drugs most patients in chronic phase now have a near-normal life expectancy. ELN 2020 mentions hydroxycarbamide only as a short course for symptomatic patients with high white cell or platelet counts while molecular and cytogenetic confirmation of CML is pending. In the US the HYDREA label () keeps the indication «resistant CML». If hydroxycarbamide was prescribed as ongoing treatment for CML and no tyrosine kinase inhibitor has been tried, consider seeking a second opinion from another hematologist.

ICD-10: C92.1

C

Myelofibrosis

Individual decision

Hydroxycarbamide is a cytostatic drug that lowers white cell and platelet counts and can shrink the spleen. The Hydrea ficha técnica (AEMPS) includes myelofibrosis (in the ficha, «myeloid splenomegaly», idiopathic myelofibrosis) among its indications, at 5 to 15 mg/kg a day. Per the European LeukemiaNet recommendations (ELN 2018), hydroxycarbamide is the first-line drug when myelofibrosis needs cytoreduction for high white cell or platelet counts. For splenomegaly in intermediate-2 and high-risk patients ELN 2018 puts ruxolitinib first and keeps hydroxycarbamide for low-risk and intermediate-1 patients; with highly symptomatic splenomegaly at intermediate-1 risk it also prefers ruxolitinib. There are no randomized trials of hydroxycarbamide in myelofibrosis, only observational data. In a retrospective series from Hospital Clínic in Barcelona (Annals of Hematology 2010, 40 patients), 40 percent achieved clinical improvement by IWG-MRT criteria; constitutional symptoms improved in 82 percent of those who had them and splenomegaly in 40 percent. A common problem is worsening anemia or pancytopenia: it developed in 18 of 40 patients, and 17 needed erythropoiesis-stimulating agents. Oral or leg ulcers appeared in 5. The choice between hydroxycarbamide, ruxolitinib and transplantation depends on risk group and disease features and is made by a hematologist.

ICD-10: D47.4

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

HIV infection

Not recommended

Hydroxycarbamide is a cytostatic drug prescribed for myeloproliferative diseases and sickle cell anemia. Around 2000 it was tested as an add-on to antiretroviral therapy for HIV, mostly with didanosine and stavudine, to suppress the virus further. It is not authorized for HIV: the labels for HYDREA and DROXIA state that it is not indicated for HIV infection, and the AEMPS and fichas técnicas give no such indication. In the ACTG 5025 RCT (AIDS 2001, 202 patients with suppressed viral load), treatment failed in 32.4 percent on hydroxycarbamide with indinavir, didanosine and stavudine, in 17.6 percent on the same regimen without it and in 7.6 percent on the previous regimen. Toxicity, not viral rebound, explained the difference. Three patients died of pancreatitis, all in the hydroxycarbamide arm. The Hydrea ficha (section 4.4) describes fatal and non-fatal pancreatitis, liver toxicity up to fatal liver failure and severe peripheral neuropathy with antiretroviral combinations, and says the combination of hydroxycarbamide with didanosine and stavudine should be avoided. In ACTG 5025 this regimen lowered CD4 counts by about 100 cells/mm³ on average. If hydroxycarbamide was prescribed to treat HIV infection, consider seeking a second opinion.

ICD-10: B20 · ICD-11: 1C62.Z

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Hydroxycarbamide inhibits ribonucleotide reductase, the enzyme a cell needs to make DNA. Rapidly dividing bone marrow cells are hit hardest, so white cell, platelet and red cell counts fall; RNA and protein synthesis are not affected. In sickle cell anemia another effect matters more: the share of fetal hemoglobin (HbF) rises, HbF interferes with the polymerization of hemoglobin S, and red cells sickle less often. Other effects help too: neutrophils decrease, and red cells hold more water and stick less to the endothelium. Absorption is rapid, with peak levels at 1 to 4 hours. It distributes through total body water, concentrates in white and red cells and crosses the blood-brain barrier. Up to half of the dose is converted through pathways that are not fully characterized, probably in the liver. CYP450 enzymes do not metabolize it in vitro, and it is not a P-glycoprotein substrate. The kidneys clear a large part of it, so the dose is reduced when creatinine clearance is below 60 mL/min. The half-life in sickle cell anemia is 6 to 7 hours.

Safety

Boxed warning

FDA boxed warning on the DROXIA and SIKLOS labels: myelosuppression and malignancies. Hydroxycarbamide may cause severe myelosuppression. It is not given if bone marrow function is markedly depressed; blood counts are checked at baseline and throughout treatment, and treatment is interrupted and the dose reduced as needed. Hydroxycarbamide is carcinogenic: patients are advised to protect themselves from the sun and are monitored for malignancies. The current HYDREA label has no boxed warning and describes the same risks in its warnings section.

Contraindications

  • Hypersensitivity to hydroxycarbamide or any excipient
  • Bone marrow depression: white cells below 2,500/mm³, platelets below 100,000/mm³ or severe anemia (Hydrea)
  • Blood counts in the toxic range in sickle cell anemia: neutrophils below 1,500/mm³, platelets below 80,000/mm³, hemoglobin below 4.5 g/dL, reticulocytes below 80,000/mm³ with hemoglobin below 9 g/dL (Siklos)
  • Current or previous skin ulcers or vasculitic ulcers with hydroxycarbamide or interferon alfa (Hydrea)
  • Severe hepatic impairment, Child-Pugh class C (Siklos)
  • Severe renal impairment, creatinine clearance below 30 mL/min (Siklos)
  • Pregnancy (Hydrea) and breastfeeding

Serious adverse effects

  • Severe, including life-threatening, myelosuppression with risk of infection and bleeding
  • Secondary leukemia and skin cancer with long-term treatment
  • Leg and foot ulcers, vasculitic ulcers and gangrene: about 9 percent of patients with myeloproliferative disease after a year of continuous treatment, more often with interferon alfa
  • Interstitial lung disease – fibrosis, pneumonitis, alveolitis, including fatal cases
  • Hemolytic anemia
  • Drug fever above 39 °C with gastrointestinal, pulmonary, hepatic, skin or cardiac involvement, usually within the first 6 weeks, requiring hospitalization
  • Pancreatitis, liver toxicity up to liver failure and severe peripheral neuropathy, including fatal cases, in patients with HIV on antiretroviral drugs, especially didanosine and stavudine
  • Cutaneous and systemic lupus erythematosus
  • Tumor lysis syndrome, seizures, hallucinations, disorientation (rare; with radiotherapy seizures and hallucinations are common)

Common adverse effects

  • Bone marrow suppression: low white cells and neutrophils, platelets and hemoglobin (very common, the main dose-limiting effect)
  • Macrocytosis, enlarged red cells unrelated to B12 or folate deficiency (very common)
  • Loss of appetite, nausea, vomiting, diarrhea, constipation, stomatitis
  • Rash, facial and peripheral redness, skin ulceration, dermatomyositis-like skin changes
  • Darkening of the skin, nails and oral mucosa, oral mucositis
  • Raised blood creatinine, urea and uric acid
  • Azoospermia and oligospermia, sometimes reversible (very common)
  • Fever, chills, malaise, weakness
  • Drowsiness, headache
  • Raised liver enzymes, cholestasis, hepatitis

Uncommon adverse effects

  • Skin cancer with long-term use
  • Vasculitic skin ulcers, more often after interferon alfa
  • Dizziness
  • Dark bands on the nails (melanonychia), hair loss, rash

Pregnancy: can you take Hydroxycarbamide?

Contraindicated in pregnancy per the Hydrea ficha técnica (sections 4.3 and 4.6); the Siklos ficha does not recommend use during pregnancy. Hydroxycarbamide can harm the fetus: it is a potent teratogen in animals, and data in pregnant women are limited. Women of childbearing potential need effective contraception during treatment and for at least 6 months afterwards, men during treatment and for at least 3 months afterwards (Hydrea ficha; the FDA label gives at least 1 year for men). The FDA asks for pregnancy status to be checked before the start. If a patient with sickle cell anemia plans a child, the Siklos ficha advises stopping treatment 3 to 6 months before conception if possible and weighing a switch to a transfusion program. The ficha asks for a pregnancy to be reported to the doctor at once. Male fertility is affected too: azoospermia or oligospermia are common and sometimes reversible, so men are offered sperm banking before treatment.

Breastfeeding: can you take Hydroxycarbamide?

Contraindicated during breastfeeding (Hydrea and Siklos fichas técnicas, section 4.3). Hydroxycarbamide passes into breast milk and may cause serious adverse reactions in the infant, so breastfeeding is stopped during treatment. The FDA label also requires stopping breastfeeding and lists carcinogenicity among the risks to the infant.

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Renal dose adjustment for all the patient's drugs

Enter the patient's kidney function and drugs. On one page you'll see the dose each label gives

Hydroxycarbamide prescribing information (FDA) →

Practical notes

Monitoring

Blood counts are the main check. Per the Hydrea ficha, hemoglobin, white cells and platelets are measured at least once a week; in polycythemia vera on a settled dose the ficha suggests a full blood count every 6 to 8 weeks. With white cells below 2,500/mm³ or platelets below 100,000/mm³ treatment is paused and counts are repeated after 3 days. Per the Siklos ficha, in sickle cell anemia blood counts are checked monthly for the first 2 months and at doses up to 35 mg/kg, and every 2 months on a stable lower dose. Liver and kidney function are checked before the start and periodically. Macrocytosis can hide folate deficiency: the Hydrea ficha advises regular folate tests, and the Siklos ficha advises preventive folic acid.

Special situations

The skin needs attention. The Hydrea ficha advises sun protection, self-examination of the skin during and after treatment and screening for secondary cancers at routine visits. With leg or foot ulcers treatment is stopped and another cytoreductive drug is used. Fever, cough or shortness of breath call for a prompt lung check: the ficha describes interstitial lung disease. Hydroxycarbamide can falsely raise readings of some continuous glucose monitoring systems, and dosing insulin from them risks hypoglycemia. It also gives falsely high urea, uric acid and lactate results. Live vaccines are avoided during treatment. The Hydrea ficha advises drinking enough fluids, especially at the start.

Timing and administration

Hydrea is taken by mouth, and the dose is based on actual or ideal body weight, whichever is lower. If a capsule is hard to swallow, the Hydrea ficha allows emptying it into a glass of water and drinking it straight away. Siklos is taken once a day, preferably in the morning before breakfast; the tablet can be split into halves or quarters or dissolved in a little water. Hydroxycarbamide is a cytostatic: capsules and tablets are handled with gloves or with hand washing before and after, the powder is not inhaled, and spills are wiped up with a damp cloth. The Hydrea and Siklos fichas advise other people, especially pregnant women, to avoid contact with the drug.
Label mentions3 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Moderateinsulinclass named in the label
    «Laboratory Test Interference: Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results…»

    FDA, section 7 · Open on DailyMed

  • ModerateInsulin
    «La hidroxicarbamida puede elevar falsamente los resultados de los sensores de glucosa de determinados sistemas de monitorización continua de glucosa (MCG), lo que puede dar lugar a hipoglucemia si la…»

    AEMPS, section 4.4 · Open on CIMA

  • Moderateinsulinaclass named in the label
    «La hidroxicarbamida puede elevar falsamente los resultados de los sensores de glucosa de determinados sistemas de monitorización continua de glucosa (MCG), lo que puede dar lugar a hipoglucemia si la…»

    AEMPS, section 4.4 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Frequently asked

What is Hydroxycarbamide used for?

Hydroxycarbamide is evaluated for the following indications with varying evidence strength: Sickle cell disease (evidence tier A), Essential thrombocythemia (evidence tier A), Polycythemia vera (evidence tier B). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Hydroxycarbamide?

Common side effects of Hydroxycarbamide (≥ 1 in 100): Bone marrow suppression: low white cells and neutrophils, platelets and hemoglobin (very common, the main dose-limiting effect), Macrocytosis, enlarged red cells unrelated to B12 or folate deficiency (very common), Loss of appetite, nausea, vomiting, diarrhea, constipation, stomatitis, Rash, facial and peripheral redness, skin ulceration, dermatomyositis-like skin changes, Darkening of the skin, nails and oral mucosa, oral mucositis, Raised blood creatinine, urea and uric acid. See the Safety section for uncommon and serious reactions.

Is Hydroxycarbamide safe during pregnancy?

Contraindicated in pregnancy per the Hydrea ficha técnica (sections 4.3 and 4.6); the Siklos ficha does not recommend use during pregnancy. Hydroxycarbamide can harm the fetus: it is a potent teratogen in animals, and data in pregnant women are limited. Women of childbearing potential need effective contraception during treatment and for at least 6 months afterwards, men during treatment and for at least 3 months afterwards (Hydrea ficha; the FDA label gives at least 1 year for men). The FDA asks for pregnancy status to be checked before the start. If a patient with sickle cell anemia plans a child, the Siklos ficha advises stopping treatment 3 to 6 months before conception if possible and weighing a switch to a transfusion program. The ficha asks for a pregnancy to be reported to the doctor at once. Male fertility is affected too: azoospermia or oligospermia are common and sometimes reversible, so men are offered sperm banking before treatment.

Is Hydroxycarbamide compatible with breastfeeding?

Contraindicated during breastfeeding (Hydrea and Siklos fichas técnicas, section 4.3). Hydroxycarbamide passes into breast milk and may cause serious adverse reactions in the infant, so breastfeeding is stopped during treatment. The FDA label also requires stopping breastfeeding and lists carcinogenicity among the risks to the infant.

Who should not take Hydroxycarbamide?

Hydroxycarbamide is contraindicated in: Hypersensitivity to hydroxycarbamide or any excipient; Bone marrow depression: white cells below 2,500/mm³, platelets below 100,000/mm³ or severe anemia (Hydrea); Blood counts in the toxic range in sickle cell anemia: neutrophils below 1,500/mm³, platelets below 80,000/mm³, hemoglobin below 4.5 g/dL, reticulocytes below 80,000/mm³ with hemoglobin below 9 g/dL (Siklos); Current or previous skin ulcers or vasculitic ulcers with hydroxycarbamide or interferon alfa (Hydrea); Severe hepatic impairment, Child-Pugh class C (Siklos). Full list in the Safety section.

Does Hydroxycarbamide carry an FDA boxed warning?

FDA boxed warning on the DROXIA and SIKLOS labels: myelosuppression and malignancies. Hydroxycarbamide may cause severe myelosuppression. It is not given if bone marrow function is markedly depressed; blood counts are checked at baseline and throughout treatment, and treatment is interrupted and the dose reduced as needed. Hydroxycarbamide is carcinogenic: patients are advised to protect themselves from the sun and are monitored for malignancies. The current HYDREA label has no boxed warning and describes the same risks in its warnings section.

Official sources

Direct links to regulator labels. Open in a new tab.

How to cite

Vancouver

Hydroxycarbamide [Internet]. Evigrade; 2026 [updated 2026 Oct 30]. Available from: https://www.evigrade.com/en/drugs/hydroxycarbamide

APA 7

Evigrade. (2026, October 30). Hydroxycarbamide. https://www.evigrade.com/en/drugs/hydroxycarbamide

Other drugs in this group

Capecitabine, Everolimus, Fluorouracil, Methotrexate, Nintedanib, Sunitinib, Vincristine